Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 10Leukemia, Myeloid, Acute 7Hematologic Neoplasms 7Leukemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 4Lymphoma 4Primary Immunodeficiency Diseases 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Multiple Myeloma 2Hemoglobinopathies 2Fanconi Anemia 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Uveal Melanoma 1Thymoma 1Thymic epithelial tumor 1Prostatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Hematologic Diseases 1Graft vs Host Disease 1Castrate Resistant Prostate Cancer (CRPC) 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Methotrexate 6ruxolitinib 4ibrutinib 4Mycophenolic Acid 3Cyclosporine 3Transplantation Conditioning 2Tacrolimus 2Sirolimus 2Prednisone 2Methylprednisolone 2Cyclophosphamide 2Calcineurin Inhibitors 2thymoglobulin 1siplizumab 1remestemcel-l 1milatuzumab 1itacitinib 1eritoran 1axatilimab 1angiotensin I (1-7) 1Saline Solution 1Rituximab 1Radiotherapy 1Proto-Oncogene Proteins c-raf 1Photopheresis 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1Panobinostat 1KRN 7000 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Graft vs Host Disease × AP 1903 reagent × Clear all
NCT01744223 2022-07-12

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Bellicum Pharmaceuticals

Phase 1/2 Active not recruiting
36 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡